LONDON / RankWire.AI / – A compound naturally derived from pomegranates has shown promise in enhancing various indicators of heart performance in experimental models of HFpEF. Urolithin A helped the heart achieve more effective relaxation between beats, while also decreasing fibrosis and abnormal growth of cardiac muscle cells. Some parameters improved by as much as 80% when compared to untreated animal models. Researchers also observed positive effects in lab-grown human heart tissue, adding further laboratory evidence to support these findings.

HFpEF, or heart failure with preserved ejection fraction, occurs when the heart continues to pump normally but fails to relax adequately, leading to impaired filling of the chambers between contractions. Patients may suffer from breathlessness, fatigue, and limited exercise capacity. This condition accounts for roughly half of all heart failure cases in the United Kingdom. Urolithin A is produced when gut microbes metabolize certain compounds present in pomegranates, walnuts, and various berries, although its production varies from person to person.
The researchers identified PKGIα, a protein that plays a vital role in maintaining normal blood vessel function and facilitating heart muscle relaxation, as the key target. Urolithin A modifies a specific part of this protein called cysteine 42, which activates a pathway associated with cardiovascular health. The study also investigated how the compound impacted heart tissue structure. King’s College London researchers reported improvements in diastolic function, decreased tissue scarring, and lessening of heart muscle cell enlargement in treated experimental models.
Laboratory Models Show Urolithin A Enhances Cardiac Relaxation
The animal studies concentrated on diastolic function, which assesses the heart’s ability to relax and fill after each beat. Models treated with urolithin A exhibited better performance in multiple measures compared to untreated controls. Additionally, fibrosis levels, which can stiffen heart tissue and hinder proper filling, were found to be lower. The reported improvements of up to 80% pertain to specific experimental metrics and do not necessarily reflect clinical outcomes or improvements in patients.
The research team also evaluated urolithin A in engineered human cardiac tissue derived from stem cells, offering a controlled environment to study human heart responses. The compound enhanced both relaxation and contraction behaviors in these lab models. Previous human studies involving urolithin A for other conditions have indicated a good safety profile. However, since this research did not involve HFpEF patients, its conclusions are limited to animal models and lab-grown human tissues.
Further Human Clinical Testing Is Required
Supported by the British Heart Foundation, the research underscored the compound’s ability to improve heart relaxation during early-stage experiments. Nonetheless, the organization emphasized that these findings do not equate to an existing treatment for HFpEF. Researchers also cautioned against interpreting the results as evidence that consuming pomegranates can cure heart failure, clarifying that the study focused on urolithin A’s biological activity, not dietary intake. No tested foods demonstrated the capacity to prevent or treat heart failure in this research.
The study highlights PKGIα cysteine 42 as a specific biological target in HFpEF investigations and offers laboratory evidence that urolithin A can activate this pathway, leading to improvements in markers related to cardiac relaxation. HFpEF frequently co-occurs with conditions like high blood pressure, obesity, and diabetes, and remains a prevalent form of heart failure globally. Clinical trials are necessary to determine whether these effects are replicable in patients and whether they translate into tangible health benefits.
